Antibodies Targeting Cancer

About

Overview The high molecular weight melanoma associated antigen, chondroitin sulphate proteoglycan 4 (CSPG4), is an early marker of melanoma progression that may be involved in stimulating tumor cell proliferation, migration and invasion. In addition to being a prognostic marker of metastasis, studies have indicated CSPG4 as a relevant biomarker and therapeutic target for melanoma and several other cancers. University of Pittsburgh cancer immunologists have discovered monoclonal antibodies specific for the cancer biomarker, CSPG4 and have developed methods of using these antibodies or antibody fragments for immunoconjugate treatment, screening, diagnosis and research of CSPG4- expressing cancers. In addition, CSPG4 antibodies and antibody fragments may be used with CSPG4 peptide mimics for immunotherapy of CSPG4- expressing cancers. Advanced pre-clinical studies show treatment with CSPG4 antibodies reduce growth, migration and adhesion of cancer in mice.   Advantages • Highly specific and sensitive for multiple CSPG4-expressing cancers • Multiple applications in cancer diagnostics, therapy and research   Applications Therapy, diagnostics and research of melanoma, head and neck squamous cell carcinoma, glioma, prostate, ovarian, colon, stomach, pancreatic or breast cancers, including: • Antibody-drug conjugates, immunotoxin therapy • Radio-immunotherapy, radio-immunoguided surgery, other immunoconjugates • PET imaging of primary tumors and metastases • ELISA, IHC, Western blot   Stage of Development • Pre-IND briefing package available   Patents US 8, 476, 410 US 9, 193, 796 Reduced growth of lung tumors treated with CSPG4-targeting antibodies in a mouse model. J Natl Cancer Inst. 2010 Oct 6; 102(19): 1496–1512.